Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30937483 | 0.88 | CSNK2A1 (0.61) | CSNK2A1TBXAS1GPR84KIF11 | |
| SCHEMBL8957520 | 0.85 | CSNK2A1 (0.53) | CSNK2A1TBXAS1GPR84KIF11 | |
| SCHEMBL14554158 | 0.81 | CSNK2A1 (0.49) | CSNK2A1TBXAS1GPR84 | |
| SCHEMBL4945471 | 0.80 | CSNK2A1 (0.56) | CSNK2A1GPR84KIF11 | |
| SCHEMBL12327114 | 0.80 | TBXAS1 (0.56) | TBXAS1CDK2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL29352833 | 0.80 | GPR84 (0.67) | CSNK2A1GPR84 | |
| SCHEMBL17027156 | 0.80 | TBXAS1 (0.56) | TBXAS1CDK2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL1242939 | 0.80 | GPR84 (0.67) | CSNK2A1GPR84 | |
| SCHEMBL2537034 | 0.77 | HTR2A (0.65) | TBXAS1MEN1CYP1A2KMT2A | |
| SCHEMBL13715393 | 0.77 | TBXAS1 (0.53) | TBXAS1CDK2MEN1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109229-B2 | Methods and compounds for treating proliferative diseases | ELI LILLY AND COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1325011-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | LILLY CO ELI (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | ENGLER THOMAS ALBERT (US) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | CDK4, CCNI, CCNA1 | CSNK2A1 129/4885TBXAS1 1968/4885CDK2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.